|
The manufacture, sale and distribution of Hydrochlorothiazide has
been approved by the U. S. Food and Drug Administration-FDA as the
supplemental new drug application-sNDA for the anti-hypertensive for
initial use in patients with hypertension who are likely required
multiple drugs for attaining their blood pressure goals and as the
adjunctive therapy in edema associated with congestive heart failure
– CHF, hepatic cirrhosis as well as corticosteroid and estrogen
therapies.
The approval is based on the data from different clinical trials
that involved over 1,200 patients with moderate or very high blood
pressure disorders. In the first double-blind, active-controlled,
seven week trial, the patients having very high hypertension with
minimum bottom line of 172 / 113 mm Hg Systolic Blood Pressure-SBP /
Diastolic Blood Pressure – DBP were randomly treated with
Hydrochlorothiazide. After one week all the doses were doubled.
After 5 weeks the patients demonstrated reduction in their mean
blood pressure of 30.8 / 24.0 mm Hg versus 21.1 / 19.3 mm Hg of SBP
/ DBP.
Guidelines support initial combination therapy for very high
hypertension based on the necessity of lowering blood pressure
within weeks instead of months. Now with the help of
Hydrochlorothiazide tablets the physicians have more therapeutic
options for treating mild, moderate to very high hypertension cases.
The drug is indicated for the treatment of hypertension and is also
said to help slowing down the progression of nephropathy in type 2
diabetic hypertensive patients.
This drug may be used in treating the patients appropriately whose
blood pressure is not sufficiently controlled on mono-therapy and
now can be used as the initial therapy in appropriate patients who
are supposed to require multiple medications for attaining their
blood pressure targets.
|
